Hospital
Hills & Dales General Hospital, INC.
Hills & Dales General Hospital, INC. was paid $7.07M by Medicaid between Jan 2018 and Dec 2024, across 197 billing codes. Its largest line is 99284, emergency room visit (serious) — 19% of everything it billed.
33Billing provider infoHILLS & DALES GENERAL HOSPITAL, INC.
CASS CITY, MI 48726
CASS CITY, MI 48726
33aNPI1154367001assigned 06/21/2006
33bProvider typeCritical Access Hospital
28Total paid$7.07M
24GClaims270,433
24DCodes billed197
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Michigan
Rank by total paid#13 of 31
Median peer was paid$6.03M
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24,287 | $618K | |
| 2019 | 36,832 | $736K | |
| 2020 | 31,780 | $806K | |
| 2021 | 25,403 | $990K | |
| 2022 | 31,680 | $1.06M | |
| 2023 | 53,572 | $1.33M | |
| 2024incomplete | 66,879 | $1.53M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 9,162 | 6,216 | $1.31M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 11,907 | 7,825 | $1.30M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 2,876 | 2,181 | $912K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.1% | 10,150 | 9,256 | $504K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.0% | 4,579 | 4,195 | $282K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.8% | 3,967 | 3,092 | $272K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.8% | 7,385 | 2,381 | $267K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.1% | 1,885 | 1,737 | $222K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.0% | 6,641 | 2,184 | $142K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.9% | 1,367 | 1,341 | $131K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.8% | 2,507 | 2,399 | $130K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.8% | 2,203 | 2,092 | $125K |
185 more codes
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.6% | 2,731 | $116K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.5% | 1,939 | $105K |
| 99204 | Doctor's office visit, new patient (more involved) | 1.1% | 918 | $76K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 1,805 | $75K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.0% | 600 | $74K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 1,738 | $74K |
| 87428 | <1% | 2,583 | $68K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,616 | $61K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,209 | $59K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,855 | $54K |
| 80061 | Lipid panel | <1% | 5,393 | $47K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,645 | $45K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 1,277 | $42K |
| 80053 | Comprehensive metabolic panel | <1% | 10,970 | $39K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 682 | $39K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 177 | $35K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,398 | $30K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,803 | $25K |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,534 | $19K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,384 | $18K |
| 62323 | <1% | 65 | $17K | |
| 97161 | <1% | 260 | $17K | |
| 97162 | <1% | 287 | $17K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 128 | $16K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,023 | $15K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,829 | $14K |
| 73630 | <1% | 432 | $12K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 527 | $10K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 522 | $10K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,505 | $10K |
| 84439 | <1% | 2,313 | $9K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,052 | $9K |
| 20611 | <1% | 155 | $8K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 65 | $8K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 219 | $8K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 464 | $7K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 54 | $7K |
| 73610 | <1% | 218 | $7K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,744 | $7K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,490 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,310 | $6K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 368 | $6K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 16 | $6K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 737 | $6K |
| 73130 | <1% | 154 | $5K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 31 | $5K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 15 | $5K |
| 94726 | <1% | 29 | $5K | |
| 73221 | <1% | 32 | $5K | |
| 87081 | <1% | 1,513 | $4K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 49 | $4K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 53 | $4K |
| 84481 | <1% | 423 | $4K | |
| 82728 | <1% | 448 | $3K | |
| 83735 | <1% | 2,362 | $3K | |
| 73030 | <1% | 84 | $3K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 48 | $3K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 74 | $3K |
| 73562 | <1% | 96 | $3K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 28 | $3K |
| 83550 | <1% | 539 | $3K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 40 | $2K |
| 82607 | <1% | 376 | $2K | |
| 20553 | <1% | 58 | $2K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 38 | $2K |
| 83540 | <1% | 599 | $2K | |
| 0012A | <1% | 61 | $2K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 68 | $2K |
| 73110 | <1% | 54 | $2K | |
| 73560 | <1% | 49 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 831 | $2K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 93 | $2K |
| 99406 | <1% | 255 | $2K | |
| 74018 | <1% | 46 | $2K | |
| 87186 | <1% | 455 | $2K | |
| 72141 | <1% | 13 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 109 | $2K |
| 87481 | <1% | 74 | $1K | |
| 87807 | <1% | 193 | $1K | |
| 86140 | <1% | 961 | $1K | |
| 80074 | <1% | 68 | $1K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 317 | $1K |
| 0011A | <1% | 67 | $1K | |
| 85610 | <1% | 818 | $1K | |
| 81025 | <1% | 1,750 | $1K | |
| 87631 | <1% | 227 | $1K | |
| 82043 | <1% | 379 | $1K | |
| 85027 | <1% | 429 | $1K | |
| 81002 | <1% | 820 | $1K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 58 | $1K |
| 81001 | <1% | 2,535 | $1K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 27 | $1K |
| 0031A | <1% | 36 | $1K | |
| 01992 | <1% | 69 | $1K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 66 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,073 | $1K |
| 72100 | <1% | 18 | $941.81 | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 12 | $907.45 |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 56 | $828.36 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 44 | $813.76 |
| 76830 | Ultrasound, transvaginal | <1% | 13 | $785.03 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 15 | $764.91 |
| 20610 | <1% | 15 | $722.10 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 210 | $716.13 |
| 87070 | <1% | 189 | $673.35 | |
| 83690 | <1% | 1,313 | $661.31 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 27 | $650.66 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 37 | $605.13 |
| 92567 | <1% | 67 | $592.57 | |
| 90686 | <1% | 36 | $534.74 | |
| 51798 | <1% | 89 | $516.22 | |
| 87077 | <1% | 149 | $473.61 | |
| 99000 | <1% | 188 | $439.06 | |
| 87806 | <1% | 32 | $429.74 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 66 | $407.05 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 28 | $406.14 |
| 96127 | <1% | 140 | $385.53 | |
| 73564 | <1% | 14 | $349.56 | |
| 81003 | <1% | 744 | $281.89 | |
| 84484 | <1% | 1,051 | $270.40 | |
| 82746 | <1% | 39 | $269.76 | |
| 85652 | <1% | 227 | $262.84 | |
| 83655 | <1% | 38 | $237.39 | |
| 83880 | <1% | 16 | $236.27 | |
| 80076 | <1% | 80 | $234.67 | |
| 87480 | <1% | 16 | $205.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,581 | $196.20 |
| 87660 | <1% | 15 | $188.39 | |
| 85651 | <1% | 91 | $167.13 | |
| 87088 | <1% | 39 | $122.90 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 20 | $114.54 |
| 93000 | <1% | 12 | $109.92 | |
| 84550 | <1% | 52 | $102.48 | |
| 86038 | <1% | 14 | $84.15 | |
| 86430 | <1% | 26 | $75.60 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 13 | $75.36 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 25 | $66.22 |
| 94010 | <1% | 41 | $47.02 | |
| 82570 | <1% | 12 | $23.05 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,744 | $6.75 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 90 | $1.81 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 998 | $0.00 |
| 1159F | 0% | 12,295 | $0.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 628 | $0.00 |
| 3077F | 0% | 1,589 | $0.00 | |
| 3078F | 0% | 9,132 | $0.00 | |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | 0% | 66 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 124 | $0.00 |
| 1033F | 0% | 538 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 129 | $0.00 |
| 94729 | 0% | 28 | $0.00 | |
| 1032F | 0% | 33 | $0.00 | |
| 3050F | 0% | 80 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 12 | $0.00 |
| 99401 | 0% | 14 | $0.00 | |
| 3074F | 0% | 10,660 | $0.00 | |
| 3079F | 0% | 3,995 | $0.00 | |
| 1036F | 0% | 3,923 | $0.00 | |
| 3049F | 0% | 259 | $0.00 | |
| 2000F | 0% | 10,559 | $0.00 | |
| 2010F | 0% | 12,257 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 1,022 | $0.00 |
| 1220F | 0% | 672 | $0.00 | |
| 3080F | 0% | 1,125 | $0.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 663 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 79 | $0.00 |
| 3008F | 0% | 222 | $0.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 111 | $0.00 |
| 1034F | 0% | 2,132 | $0.00 | |
| 1125F | 0% | 2,434 | $0.00 | |
| 3017F | 0% | 214 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 1,267 | $0.00 |
| 2001F | 0% | 155 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 85 | $0.00 |
| J3490 | Unclassified drugs | 0% | 124 | $0.00 |
| 3048F | 0% | 235 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 724 | $0.00 |
| 3075F | 0% | 2,065 | $0.00 | |
| 97802 | 0% | 13 | $0.00 | |
| 84703 | 0% | 12 | $0.00 | |
| 83605 | 0% | 115 | $0.00 | |
| 94760 | 0% | 71 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 42 | $0.00 |
| 3014F | 0% | 14 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCASTLE, WILLIAM (CFO)